153 related articles for article (PubMed ID: 22227958)
1. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
Samoš M; Stančiaková L; Ivanková J; Staško J; Kovář F; Dobrotová M; Galajda P; Kubisz P; Mokáň M
J Thromb Thrombolysis; 2015 Jan; 39(1):95-100. PubMed ID: 25103614
[TBL] [Abstract][Full Text] [Related]
3. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
4. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Avecilla ST; Ferrell C; Chandler WL; Reyes M
Am J Clin Pathol; 2012 Apr; 137(4):572-4. PubMed ID: 22431533
[TBL] [Abstract][Full Text] [Related]
5. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
6. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
7. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
8. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
9. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
10. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
11. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
13. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
Gosselin R; Hawes E; Moll S; Adcock D
Am J Clin Pathol; 2014 Feb; 141(2):262-7. PubMed ID: 24436275
[TBL] [Abstract][Full Text] [Related]
14. A specific antidote for dabigatran: functional and structural characterization.
Schiele F; van Ryn J; Canada K; Newsome C; Sepulveda E; Park J; Nar H; Litzenburger T
Blood; 2013 May; 121(18):3554-62. PubMed ID: 23476049
[TBL] [Abstract][Full Text] [Related]
15. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
[TBL] [Abstract][Full Text] [Related]
17. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.
Samuelson BT; Cuker A; Siegal DM; Crowther M; Garcia DA
Chest; 2017 Jan; 151(1):127-138. PubMed ID: 27637548
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
Jaffer IH; Chan N; Roberts R; Fredenburgh JC; Eikelboom JW; Weitz JI
J Thromb Haemost; 2017 Dec; 15(12):2377-2387. PubMed ID: 28976630
[TBL] [Abstract][Full Text] [Related]
20. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]